Company news
Modalis Therapeutics Corporation (TSE:4883) news
Modalis Therapeutics Corporation news releases on 6ix. Latest, Sep 10, 2026: Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular…
Press releases & updates
Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular Dystrophy
September 10, 2026
(Correction) Regarding Corrections to the "Consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]"
August 13, 2026
Consolidated Financial Results for the Six Months Ended June 30, 2026 [Japanese GAAP]
August 10, 2026
Business Plans and Matters Related to Growth Potential
July 14, 2026
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
December 24, 2025
Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
May 12, 2025
Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration
October 28, 2024
Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).
October 25, 2024
Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
September 30, 2024
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
May 7, 2024
Modalis Announces updated strategic plan and business consolidation of US operation
April 15, 2024
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting
April 19, 2023
Modalis Therapeutics : Notice Regarding Determination of Terms and Conditions of Stock Options (Share Acquisition Rights)
July 5, 2022
Modalis Therapeutics : Notice Regarding a Patent Allowance for ‘Method for treating muscular dystrophy by targeting utrophin gene’ in the USA
June 22, 2022
Modalis Therapeutics : Notice Regarding of Issuance of Stock Options (Share Acquisition Rights)
June 15, 2022
Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Modulating Medicines for the Treatment of a Type of Muscular Dystrophy and the Other Genetic Disorders at the ASGCT Annual Meeting
April 20, 2022
Modalis Therapeutics : Business Plans and Matters Related to High Growth Potential
March 29, 2022
Modalis Therapeutics : Announcement of Issuance of Stock Options (Share Acquisition Rights)
March 29, 2022
Modalis Therapeutics : Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
February 22, 2022
Modalis Therapeutics : Announces Termination of Research Collaboration on MDL-204
January 7, 2022